Clinical trials: Obesity, Overweight
Healthy
A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)
Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection.
- Trial name
- NCT07388667
- Testing
- MK-4082
- Where
- 4 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Apnea
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
The primary objectives of this study are to evaluate the safety and efficacy of VI-0521 compared to placebo in the treatment of obese adults with obstructive sleep apnea (OSA) and to assess the relative contributions of weight…
- Trial name
- NCT00745251
- Testing
- VI-0521
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- VIVUS LLC
Obesity or Overweight, Cardiovascular Disease
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-5 (NCT07843472)
- Testing
- Petrelintide
- Where
- 3 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Obesity
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control.
- Trial name
- NCT05579977
- Testing
- PF-07081532, Rybelsus
- Where
- 90 sites in United States, Bulgaria and 6 more
- Volunteers
- 902 people
- Sponsor
- Pfizer
Overweight and Obesity, Type2diabetes
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.
- Trial name
- LIBERATE-1 (NCT05670379)
- Testing
- Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vivani Medical, Inc
Obesity
Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study
This research study is being performed to find out if a new device, AspireAssist Aspiration Therapy System, can help people with obesity to lose weight without causing too many side effects.
- Trial name
- PATHWAY (NCT01766037)
- Testing
- Aspiration Therapy (AspireAssist), Lifestyle Therapy
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- Aspire Bariatrics, Inc.
Obesity
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Single ascending dose of HM15211 in healthy obese subjects.
- Trial name
- NCT03374241
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Overweight and Obesity
Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity
Clinical trial, multicenter, double-blind, placebo-controlled, comparative of three parallel groups, randomized treatment to assess the efficacy and safety using a fixed dose combination of metformin hydrochloride with fluoxetine…
- Trial name
- Metfluo (NCT03051451)
- Testing
- combination metformin hydrochloride/ fluoxetine 500/20 mg, combination metformin hydrochloride/ fluoxetine 1000/20mg
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Obesity
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05111912
- Testing
- XW003, Saxenda
- Where
- Australia
- Volunteers
- 206 people
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Overweight, Obesity
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in…
- Trial name
- NCT07229157
- Testing
- Maridebart Cafraglutide, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Amgen
Obesity, Obesity-related Complications
Pre-approval Expanded Access of Retatrutide (LY3437943)
Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass…
- Trial name
- NCT07629401
- Testing
- Retatrutide
- Sponsor
- Eli Lilly and Company
Obesity
Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials
Roche and GSK will carry out a meta-analysis of liver function data from trials of orlistat to establish whether there is any indication of liver toxicity.
- Trial name
- NCT01332448
- Testing
- Orlistat 120, Orlistat 60
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Obesity, Overweight
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin
- Trial name
- NCT06064006
- Testing
- NNC0487-0111
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obese Volunteers
Evaluate LAE102 in Healthy and Overweight/Obese Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose…
- Trial name
- NCT06493084
- Testing
- LAE102 intravenous administration, LAE102 subcutaneous administration, LAE102 multiple subcutaneous administration
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Laekna Limited
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07855133
- Testing
- Semaglutide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2…
- Trial name
- NCT03444584
- Testing
- MEDI0382, Dapaglifozin, Metformin
- Where
- 8 sites in Germany, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Obesity
SUCCESS Tracking Study
The overall purpose of this research is to evaluate the long-term outcomes associated with participation in Medifast Direct and Take Shape For Life weight-loss programs in comparison with non-Medifast weight-loss programs.
- Trial name
- NCT01021917
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Medifast, Inc.
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Overweight and Obesity
Evaluation of Libramed in Obesity Treatment
Randomized, double-blind, placebo-controlled study aimed at evaluating the effects of a 3-months treatment with Policaptil Gel Retard on postprandial incretin hormones release and satiety in obese women
- Trial name
- ELOT (NCT03537235)
- Testing
- Libramed
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Aboca Spa Societa' Agricola
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.